A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination
with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer
(MIBC). Patients with pre-specified tumor mutations and complete clinical response with
neoadjuvant therapy will preserve their bladders and go on active surveillance.